Brief: Immunicum Gets FDA Fast Track Designation For Ilixadencel In Gastrointestinal Stromal Tumors
07/12/2020 07:07
Dec 7 (Reuters) - Immunicum AB IMMUN.ST :
* REG-IMMUNICUM AB (PUBL) RECEIVES FDA FAST TRACK
DESIGNATION FOR
ILIXADENCEL IN GASTROINTESTINAL STROMAL TUMORS (GIST)
* TRIAL MET PRIMARY ENDPOINT OF SAFETY SHOWING THAT
ILIXADENCEL IN
COMBINATION WITH TKIS MAINTAINED A FAVORABLE SAFETY PROFILE WITH
NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS
Source text for Eikon: ID:nGNE1mnvpS
Further company coverage: IMMUN.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587696600;))